Needham & Company Maintains a 'Buy' on Seattle Genetics (SGEN); Q2 Preview of Adcetris Sales
Tweet Send to a Friend
Needham & Company maintains a 'Buy' on Seattle Genetics (NASDAQ: SGEN).
Analyst, Alan Carr, said, "SGEN is expected to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Analyst, Alan Carr, said, "SGEN is expected to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE